# An accurate, affordable, and transferable assay for minimally invasive detection of esophageal squamous cell carcinoma (ESCC) in Africa and the United States

> **NIH NIH R42** · CAPSULOMICS, LLC · 2024 · $885,000

## Abstract

Esophageal squamous cell carcinoma (ESCC), comprising 90% of esophageal cancer (EC) worldwide,
has a 5-year fatality rate of 90% in low- to moderate-income countries, or LMICs, primarily due to an
inability to diagnose the disease before it becomes fatal. Indeed, the value of low-cost, accurate, and
assessable diagnostics is central to the current Notice of Special Interest (NOSI) we are responding to,
which highlights EC as one of the four “highest-priority cancers” (NCI SBIR/STTR Program
Announcement Regarding Cancer Prevention, Diagnosis, and Treatment Technologies for Low-
Resource Settings, NOT-CA-21-062). To address this pressing need, we developed an affordable,
accessible, safe, and accurate diagnostic strategy applying our novel ESCC-specific methylated DNA
biomarkers to esophageal cells retrieved using our noninvasive, swallowable sponge-capsule device. In
our Phase I studies (n = 94), we developed, optimized, and validated a multivariate biomarker panel,
which accurately diagnosed ESCC in sponge-capsule samples (sensitivity = 92.3%, specificity =
86.7%; AUC = 0.94). Building on this success, our Phase II project will perform a robust independent
validation of this assay and achieve commercialization in the USA while implementing assessments and
feedback toward early commercialization in Uganda, an LMIC. In Aim 1, we will transfer the EsoFind
assay from Johns Hopkins University to Capsulomics and perform extensive analytical validation,
simplifying workflow to improve throughput, efficiency, and accuracy while reducing cost and complexity.
In Aim 2, a cohort of 300 new patients from the US and Uganda will be studied to develop rigorous
models using advanced biostatistical methods, including earlier ESCC cases. We will first generate data
in a training set (n=200 patients), building new models based on our SBIR Phase I biomarker panel
(cg20655070, SLC35F1, TAC1, ZNF132, and ZNF542) but also including clinical features (e.g., age and
gender). We will then independently validate this new algorithm in a test set (n=100 patients) for
validation. Finally, Aim 3 will focus on establishing the commercialization of EsoFind in the USA,
including submission for FDA clearance of our sponge-based Cell Extraction Device (CED) and
preparation for its launch as a Laboratory Developed Test (LDT). Additionally, we will garner user
feedback in Uganda, while developing a plan for transfer and marketing as a model for use in other
LMICs. Thus, this Phase II SBIR project will streamline, expand, validate, and achieve early
commercialization of this safe, affordable, accurate, noninvasive streamlined assay to diagnose ESCC
in the USA and Uganda. If successful, our strategy has the potential to be applied in larger, longer-term
asymptomatic at-risk population-based screening studies to improve ESCC detection and survival.

## Key facts

- **NIH application ID:** 10921933
- **Project number:** 2R42CA261376-02A1
- **Recipient organization:** CAPSULOMICS, LLC
- **Principal Investigator:** Sarah Laun
- **Activity code:** R42 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $885,000
- **Award type:** 2
- **Project period:** 2021-09-21 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10921933

## Citation

> US National Institutes of Health, RePORTER application 10921933, An accurate, affordable, and transferable assay for minimally invasive detection of esophageal squamous cell carcinoma (ESCC) in Africa and the United States (2R42CA261376-02A1). Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/grant/nih/10921933. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*